Abstract
It is widely accepted that blood coagulation in vivo is initiated during normal hemostasis, as well as during intravascular thrombus formation, when the cell-surface protein, tissue factor, is exposed to the blood as a consequence of vascular injury. In addition to its essential role in hemostasis, tissue factor may be also implicated in several pathophysiological processes, such as intracellular signaling, cell proliferation, and inflammation. For these reasons, the tissue factor:factor VIIa complex has been the subject of intense research focus. Many experimental studies have demonstrated that inhibition of tissue factor:factor VIIa procoagulant activity are powerful inhibitors of in vivo thrombosis and that this approach usually results in less pronounced bleeding tendency, as compared to other “more classical” antithrombotic interventions. Alternative approaches may be represented by transfecting the arterial wall with natural inhibitors of tissue factor:factor VIIa complex, such as tissue factor pathway inhibitor, which may result in complete inhibition of local thrombosis without incurring in potentially harmful systemic effects. Additional studies are warranted to determine the efficacy and safety of such approaches in patients.
Keywords: tissue factor coagulation pathway, hemostasis, tissue factor, factor VIIa procoagulant, antithrombotic interventions
Current Vascular Pharmacology
Title: Inhibition of the Tissue Factor Coagulation Pathway
Volume: 2 Issue: 4
Author(s): Paolo Golino, Lavinia Forte and Salvatore De Rosa
Affiliation:
Keywords: tissue factor coagulation pathway, hemostasis, tissue factor, factor VIIa procoagulant, antithrombotic interventions
Abstract: It is widely accepted that blood coagulation in vivo is initiated during normal hemostasis, as well as during intravascular thrombus formation, when the cell-surface protein, tissue factor, is exposed to the blood as a consequence of vascular injury. In addition to its essential role in hemostasis, tissue factor may be also implicated in several pathophysiological processes, such as intracellular signaling, cell proliferation, and inflammation. For these reasons, the tissue factor:factor VIIa complex has been the subject of intense research focus. Many experimental studies have demonstrated that inhibition of tissue factor:factor VIIa procoagulant activity are powerful inhibitors of in vivo thrombosis and that this approach usually results in less pronounced bleeding tendency, as compared to other “more classical” antithrombotic interventions. Alternative approaches may be represented by transfecting the arterial wall with natural inhibitors of tissue factor:factor VIIa complex, such as tissue factor pathway inhibitor, which may result in complete inhibition of local thrombosis without incurring in potentially harmful systemic effects. Additional studies are warranted to determine the efficacy and safety of such approaches in patients.
Export Options
About this article
Cite this article as:
Golino Paolo, Forte Lavinia and Rosa De Salvatore, Inhibition of the Tissue Factor Coagulation Pathway, Current Vascular Pharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570161043385402
DOI https://dx.doi.org/10.2174/1570161043385402 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Platelets in Thrombosis and Hemostasis: Old Topic with New Mechanisms
Cardiovascular & Hematological Disorders-Drug Targets Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology Assessment of Vascular Geometry for Bilateral Carotid Artery Ligation to Induce Early Basilar Terminus Aneurysmal Remodeling in Rats
Current Neurovascular Research Multiple Roles of Biosurfactants in Biofilms
Current Pharmaceutical Design Retrograde Coronary Chronic Total Occlusion Intervention
Current Cardiology Reviews The Modification of Serum Lipids after Acute Coronary Syndrome and Importance in Clinical Practice
Current Cardiology Reviews Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Current Drug Targets Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Mechanisms, Prevention and Treatment of Distal Embolization
Current Pharmaceutical Design Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry